Clinical Scorecard: Oncolytic Virotherapy Mitigates the Selection of IFN-Resistant Tumor Cells Following Immunotherapy, Yet Faces Challenges from the Rise of Dedifferentiated Tumor Cells

At a Glance

Key Highlights

• Loss of IFN signaling allows tumor cells to evade immune surveillance.
• Oncolytic virotherapy can selectively target IFN-unresponsive tumor cells.
• Dedifferentiated tumor cells can emerge post-therapy, resisting treatment.
• Natural Killer (NK) cells eliminate IFN-unresponsive subclones in vivo.
• Combination strategies may enhance the efficacy of immunotherapy.

Guideline-Based Recommendations

Diagnosis

• Monitor for genetic mutations affecting IFN signaling in melanoma.

Management

• Consider sequential oncolytic virotherapy following immunotherapy.

Monitoring & Follow-up

• Assess tumor cell response to treatment and emergence of resistant phenotypes.

Risks

• Potential for dedifferentiated tumor cells to resist both immune and viral therapies.

Patient & Prescribing Data

Patients with melanoma exhibiting resistance to immune checkpoint inhibitors.

Sequential immuno-virotherapy may counteract IFN-resistant tumor cell emergence.

Clinical Best Practices

• Utilize genetic screening to identify IFN signaling deficiencies.
• Incorporate oncolytic virotherapy in treatment regimens for resistant tumors.
• Monitor for dedifferentiation in tumor cells during treatment.

Related Resources & Content

• Clinical transcriptomic studies on IFN signatures
• CRISPR-based genetic screens on IFN signaling
• Emergence of tumor cell variants linked to ICI resistance